View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 29, 2019updated 23 Dec 2019 9:41am

GSK initiates Phase III programme of gepotidacin antibiotic

GlaxoSmithKline (GSK) has initiated the Phase III EAGLE clinical programme of its investigational antibiotic, gepotidacin, for the treatment of uncomplicated urinary tract infection (uUTI, acute cystitis) and urogenital gonorrhoea (GC).

GlaxoSmithKline (GSK) has initiated the Phase III EAGLE clinical programme of its investigational antibiotic, gepotidacin, for the treatment of uncomplicated urinary tract infection (uUTI, acute cystitis) and urogenital gonorrhoea (GC).

Gepotidacin belongs to the triazaacenaphthylene bacterial topoisomerase inhibitors antibiotic class. The drug specifically acts on the DNA gyrase and topoisomerase IV enzymes involved in bacterial replication.

The Phase III programme of gepotidacin comprises EAGLE-1 and EAGLE-2 trials. Dosing of patients in the programme has already been commenced.

EAGLE-1 will evaluate oral gepotidacin compared to intramuscular ceftriaxone in combination with oral azithromycin over 21 days in around 600 participants with GC caused by Neisseria gonorrhoea (NG).

The trial’s primary endpoint is the culture-confirmed NG eradication from the urogenital body site during the test-of-cure (TOC) visit.

EAGLE-2 is designed to compare oral gepotidacin to the oral dose of a first-line antibiotic called nitrofurantoin over 28 days in around 1,200 uUTI patients.

The trial will measure therapeutic response at the TOC visit as the primary endpoint in patients with qualifying uropathogens.

Initial results from the trials are expected to be reported by the end of 2021.

GSK chief scientific officer and R&D president Dr Hal Barron said: “Given the increasing rate of antibiotic drug resistance, and gepotidacin’s unique mechanism of action, we believe this drug has the potential to transform the treatment landscape for patients with uncomplicated urinary tract infection and urogenital gonorrhoea who currently have limited therapeutic options.”

The Phase III programme is supported by positive data from two Phase II trials, which tested gepotidacin in patients with GC and acute bacterial skin and skin structure infections (ABSSSI).

GSK noted that the antibiotic’s development is made possible through an alliance with the US Biomedical Advanced Research and Development Authority (BARDA) and Defense Threat Reduction Agency (DTRA).

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena